Buscar ubicaciones
Para conocer los horarios, visitas sin turno y citas.No se pudo cargar la navegación global.
Human Immunodeficiency Virus 1 (HIV-1) PhenoSense GT® Plus Integrase (Monogram® Phenotype + Genotype)
CPT:
87900; 87901; 87903; 87904(x16); 87906
Synonyms
- HIV Resistance
- PhenoSense GT® Plus Integrase
Test Includes
This assay is a combined assay in which HIV resistance phenotype and HIV resistance genotype is performed.
Special Instructions
A separate frozen specimen is required for each frozen test ordered.
Expected Turnaround Time
19 - 23 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
For more information, please view the literature below.
HIV-1 Lifecycle, Drugs, and Susceptibility Assays
Specimen Requirements
Specimen
Plasma, frozen
Volume
5 mL
Collection
Collect specimen in three lavender-top (EDTA) tubes or three PPT™ tubes. Do not use green-top (heparin) tubes. Centrifuge specimen within six hours of collection. Transfer plasma to one or more polypropylene screw-capped tube(s) (not "pop-top" or "snap-cap") and freeze. Ship specimen frozen. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Storage Instructions
Freeze.
Causes for Rejection
PPT™ not centrifuged; quantity not sufficient for analysis; heparinized plasma; nonfrozen specimens; specimens exposed to repeated freeze/thaw cycles; specimen received in "pop-top" or "snap-cap" tube
Test Details
Use
Determines viral phenotype and genotype resistance to four classes of commonly prescribed antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), and integrase inhibitors (INI).
Limitations
This procedure should be used for patients with documented HIV-1 infection and viral loads ≥500 copies/mL. If there is insufficient virus to produce results, HIV-1 RNA quantitation will be performed to confirm viral load, and this procedure will be billed at the account's prevailing fee.
Methodology
Phenotype: polymerase chain reaction (PCR) amplification and viral culture; Genotype: polymerase chain reaction (PCR) and DNA sequencing. PhenoSense® and PhenoSense GT® are trademarks of Monogram Biosciences®.
References
Boyd SD, Maldarelli F, Sereti I, et al. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther. 2011; 16(2):257-261. 21447876
Cohen C, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy (Tx): A randomized trial (VIRA3001), San Francisco, Calif: Seventh Conference on Retroviruses and Opportunistic Infections. 2000. Abstract 237.
Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial. Lancet. 1999 Jun 26; 353(9171):2195-2199. Erratum: Lancet. 1999; 354(9184):1128. 10392984
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Washington, DC: Department of Health and Human Services. January 28, 2000. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 10, 2012.
Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, Petropoulos CJ. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr. 2002 Oct 1; 31(2):128-136. 12394790
Walworth CM, Ward D, Napolitano L, et al. Optimized antiretroviral drug selection achieves rapid and sustained supression of viral replication, despite transmission of HIV-1 exhibiting resistance to 5-drug classes. International Workshop on HIV and Hepatitis Virus. June 5-9, 2012, Stiges, Spain.
Young B, Fransen S, Greenberg KS, et al. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: Case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther. 2011; 16(2):253-256. 21447875
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 551920 | PhenoSenseGT(R) plus Integrase | 551921 | PSGT plus Integrase PDF | 51969-4 | ||
| 551920 | PhenoSenseGT(R) plus Integrase | 551922 | PSGT+IN Net Assessment | 83326-9 | ||
| 551920 | PhenoSenseGT(R) plus Integrase | 551923 | PSGT+IN Phenotype Results | 49665-3 | ||
| 551920 | PhenoSenseGT(R) plus Integrase | 551924 | PSGT+IN Genotype Results | 80689-3 | ||
| 551920 | PhenoSenseGT(R) plus Integrase | 551925 | PSGT+IN Interpretation | 77202-0 |
| Reflex Table for PSGT+IN Net Assessment | ||||||
|---|---|---|---|---|---|---|
| Order Code | Order Name | Result Code | Result Name | UofM | Result LOINC | |
| Reflex 1 | 550504 | Quant, RNA PCR | 550497 | HIV-1 RNA by PCR | copies/mL | 20447-9 |
| Reflex Table for PSGT+IN Net Assessment | ||||||
|---|---|---|---|---|---|---|
| Order Code | Order Name | Result Code | Result Name | UofM | Result LOINC | |
| Reflex 1 | 550504 | Quant, RNA PCR | 550498 | log10 HIV-1 RNA | log10copy/mL | 29541-0 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf